This multicenter, prospective observational study is published in Frontiers in Clinical Diabetes and Healthcare. “Pre-treatment assessment of eating behavior patterns may help predict who will benefit ...

Eli Lilly LLY announced positive top-line data from a late-stage head-to-head study evaluating its once-daily small molecule (non-peptide) oral GLP-1 receptor agonist, orforglipron, compared to Novo ...

Preclinical experiments and an ongoing phase 1 trial suggest that RES-010 may complement and enhance the efficacy of ...

Compared with usual care, GLP-1 receptor agonists tirzepatide and semaglutide may be cost-effective options for patients with ...

Learn how Orforglipron oral GLP-1 pill treats obesity and type 2 diabetes, supporting weight loss and glucose control. Discover benefits today!

Psoriasis patients treated with glucagon-like peptide-1 receptor agonists (GLP-1RAs) face a 78% lower risk of death and a 44% ...

Psoriasis patients treated with glucagon-like peptide-1 receptor agonists (GLP-1RAs) face a 78% lower risk of death and a 44% ...

Paris, France, Thursday, 18 September 2025) Psoriasis patients treated with glucagon-like peptide-1 receptor agonists (GLP-1RAs) face a 78% lower ...

Novo Nordisk NVO announced positive data from a sub-analysis of its phase III REDEFINE 1 study assessing the efficacy and ...

GLP-1 receptor agonists like Ozempic can be a lifeline for people with diabetes - helping stabilize blood glucose and lose ...